Tralokinumab
Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13 (IL-13), a key Th2 cytokine that drives skin barrier disruption, sensitization, and chronic inflammation in atopic dermatitis and contributes to airway inflammation in asthma. By blocking IL-13 from binding to its receptor, it reduces eosinophilic inflammation, IgE production, and epithelial barrier dysfunction. It is approved for moderate-to-severe atopic dermatitis in adults inadequately controlled by topical therapies.
Therapeutische Bereiche
Wirkmechanismus
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13 (IL-13), a key Th2 cytokine that drives skin barrier disruption, sensitization, and chronic inflammation in atopic dermatitis and contributes to airway inflammation in asthma. By blocking IL-13 from binding to its receptor, it reduces eosinophilic inflammation, IgE production, and epithelial barrier dysfunction. It is approved for moderate-to-severe atopic dermatitis in adults inadequately controlled by topical therapies.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Tralokinumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1743081. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tralokinumab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tralokinumab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tralokinumab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tralokinumab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tralokinumab"></drugfyi-drug>